Who are the leading innovators in COVID recombinant spike … – Pharmaceutical Technology

According to GlobalDatas Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

COVID recombinant spike proteins is a key innovation area in Covid-19

COVID recombinant spike protein is a glycoprotein that mediates membrane fusion and viral entry. The full-length S protein consists of an extracellular domain (ECD), divided into a S1 and S2 subunit, a transmembrane domain and a short cytoplasmic domain. Recombinant spike-based proteins were developed by immunization of animal models to evaluate these subunit-based antigens for potential use as vaccine candidates.

GlobalDatas analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 260+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of COVID recombinant spike proteins.

Key players in COVID recombinant spike proteins a disruptive innovation in the pharmaceutical industry

Application diversity measures the number of applications identified for each patent. It broadly splits companies into either niche or diversified innovators.

Geographic reach refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from global to local.

Source: GlobalData Patent Analytics

Sanofi is one of the leading patent filers in COVID recombinant spike proteins. Sanofi is a major pharmaceutical company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis, human vaccines for protection against various bacterial and viral diseases, and other diseases. VidPrevtyn Beta is one of its approved Covid-19 vaccines, which acts by targeting 2019 Novel corona Virus Spike Glycoprotein (E2 or Peplomer Protein or S). C. H. Boehringer Sohn and Takeda Pharmaceutical are some of the other key patent filers in COVID recombinant spike proteins.

In terms of application diversity, Regeneron Pharmaceuticals leads the pack, while Akston Biosciences and Excivion stood in the second and third positions, respectively. By means of geographic reach, S Curevac held the top position, followed by Excivion and Theravectys.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalDatas latest thematic research report on Pharmaceutical.

From

Blending expert knowledge with cutting-edge technology, GlobalDatas unrivalled proprietary data will enable you to decode whats happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalDatas Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the worlds largest industries.

Read more from the original source:

Who are the leading innovators in COVID recombinant spike ... - Pharmaceutical Technology